NCT01148108

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Telik · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.

Conditions

• Mantle Cell Lymphoma
• B Cell Lymphoma
• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Canfosfamide HCl for injection	30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2010-06-22
• Last updated: 2013-03-15

Locations

1 site across 1 country: United States